Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.
about
Regulation of glucose homeostasis by GLP-1One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trialMechanisms of action of glucagon-like peptide 1 in the pancreasCardiovascular safety of anti-diabetic drugsBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingIncretins and the intensivist: what are they and what does an intensivist need to know about them?Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic miceThe entero-insular axis: implications for human metabolism.Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life spanβ-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment.Role and development of GLP-1 receptor agonists in the management of diabetes.Prkar1a in the regulation of insulin secretion.Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence?A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus.Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.Neonatal exendin-4 reduces growth, fat deposition and glucose tolerance during treatment in the intrauterine growth-restricted lamb.Snapin mediates incretin action and augments glucose-dependent insulin secretionTherapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass.The role of incretins in glucose homeostasis and diabetes treatment.Differential protective effects of exenatide, an agonist of GLP-1 receptor and Piragliatin, a glucokinase activator in beta cell response to streptozotocin-induced and endoplasmic reticulum stressesDynamics of insulin secretion and the clinical implications for obesity and diabetesChronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes.L-cysteine reversibly inhibits glucose-induced biphasic insulin secretion and ATP production by inactivating PKM2The role of gut hormones in glucose homeostasisPKA Enhances the Acute Insulin Response Leading to the Restoration of Glucose Control.Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation.The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions.The role of incretin therapy at different stages of diabetes.Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans.Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice.Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets.Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetesThe role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes.Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent.Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.Exenatide: a new option for the treatment of type 2 diabetes.Management of Type 2 diabetes: the role of incretin mimetics.
P2860
Q24563430-CAD4E75F-B2CC-48FF-AD89-7A4BDC1E83EEQ24656644-AB014C9D-FFDC-491F-8571-CC90D41931CEQ24683764-A8BD5666-DDFD-46CE-929B-E98A60EC93B1Q26741082-8AD4DF32-F5EB-4BE2-89E4-0308B40020FEQ26992979-09B34E95-400A-417B-9E2F-1EA2CC7C5020Q26995464-8EAA9A8E-9590-4FAF-A13A-0A0CF537E58FQ28546996-75C276D2-637E-4963-B06C-B2196240B205Q30365939-9FB2E177-F188-4328-91E4-1BCEF9AFA1F6Q30572405-40A6A036-57B4-46C8-8D0D-8161FDDDD2CDQ33570085-D7CB79EF-4623-44F0-AC62-B0CD902B6751Q33635830-8EB88483-9E67-497A-A67B-20AA3F5D65D3Q33664930-92AA8C90-D0CC-4423-8135-E0A27D29CE6DQ33789529-71679971-9271-4FDF-9AFF-A81E77FE2A74Q34374321-215CC042-98E0-4203-B48C-A2D8D2CF615EQ34374336-F3E1D8E5-B6D7-48BF-B393-E3907D865F99Q34530205-7F58135D-36A7-43EF-8984-34D1B9AD9A64Q34543003-09756A34-8210-4D31-A1B0-BB0CA8053795Q34592864-56E366DF-32D7-4C44-A4DD-6D1533FB73FAQ34648996-BEED0DBC-4CE6-476B-B216-670C7F7B2394Q34750027-DCA32778-2798-4C26-8694-766479DFA7D4Q34901533-5F6917BA-A1A8-491C-9812-A720426B6850Q34998652-C2CE969F-36E7-48AD-8E0F-8C6A2A71235BQ35015726-9A4906A7-E6FF-4B3A-B809-930D86102A4EQ35179893-BDE8F5E2-6685-4249-96D7-393C2D726DFFQ35189922-2B958992-7D8E-42B7-89E1-C8A8CFE9A954Q35251016-EEBB0165-6D26-431A-89F5-A073469A5946Q35532241-DEEBCA63-53A7-412E-ADB7-9CC5351D2917Q35585661-A7BB2D31-B9E1-4F93-AE91-A367EE9357ABQ35688754-4301B847-51F0-4BDA-A4DF-DE97C1598887Q35760288-33562F06-DC23-4552-9B75-B6819549971AQ35769564-416BDECD-2627-4C77-9309-162C0CD68003Q35801801-6769A9A3-EB2B-433F-A71E-6FD0C57CA629Q35994230-D6C028DF-D7A0-402C-9568-2F31097EC004Q36012896-97C48CEC-81EA-4E4D-A6C2-840E45B6749CQ36182540-9F141B69-6B23-4C1F-8141-CD97FA6075B7Q36302662-BD603ADD-2009-45BE-A0D4-8F89687E969DQ36585213-4D3BC85C-6BA8-4B8F-9998-476516CC9340Q36593147-B26F73B7-FC0A-453C-A854-DA134F0927E7Q36598110-595EFF47-CDB6-41FC-B61A-29D2C2B10CCBQ36613938-AA9FE495-4711-41B5-A676-E5B8BA665D5E
P2860
Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Exenatide augments first- and ...... subjects with type 2 diabetes.
@en
Exenatide augments first- and ...... subjects with type 2 diabetes.
@nl
type
label
Exenatide augments first- and ...... subjects with type 2 diabetes.
@en
Exenatide augments first- and ...... subjects with type 2 diabetes.
@nl
prefLabel
Exenatide augments first- and ...... subjects with type 2 diabetes.
@en
Exenatide augments first- and ...... subjects with type 2 diabetes.
@nl
P2093
P921
P356
P1476
Exenatide augments first- and ...... subjects with type 2 diabetes.
@en
P2093
Amy E Halseth
Dennis D Kim
Frauke Fehse
Loretta L Nielsen
Mark S Fineman
Michael A Nauck
Michael Trautmann
Nuwan Nanayakkara
P304
P356
10.1210/JC.2005-1093
P407
P577
2005-09-06T00:00:00Z